High-dose cabergoline for microprolactinoma remission

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, randomized, open-label Phase 3 trial comparing a short (~6 month) high-dose cabergoline regimen to the standard approach of using the lowest dose needed to normalize prolactin for two years. Eligible participants are treatment-naïve premenopausal women with MRI-confirmed microprolactinomas and prolactin at least twice the local upper limit of normal. Participants will be randomized to one of two unblinded groups and followed for remission as the primary outcome, with similar final cumulative cabergoline exposure across groups. The multicenter design includes sites in Brazil and aims to provide data that could inform future dosing strategies for microprolactinoma management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Willing and able to provide written informed consent prior to any study-related procedures
* 2\. Adults \>18 years old
* 3\. Pre-menopausal women
* 4\. Presence of signs and symptoms matching prolactinoma
* 5\. Hyperprolactinemia, defined as a prolactin (PRL) level ≥2 times the local laboratory maximum level of normality, present at the time of enrolment
* 6\. Presence of an identifiable pituitary mass on MRI with a maximum diameter of less than 1cm, independently of Knosp/invasiveness of the cavernous sinus
* 7\. Treatment naïve
* 8\. Females who engage in heterosexual intercourse must agree to use either a highly effective or a clinically acceptable method of contraception from the beginning of screening to the last study visit, which will include:
* Hysterectomy or bilateral salpingectomy
* Bilateral tubal occlusion or ligation
* Vasectomized partner
* Intrauterine device (copper or hormonal)
* Progestogen-only contraception (oral, injectable or implantable)
* Male or female condom with or without spermicide
* Sexual abstinence (only when it is the usual and preferred lifestyle of the subject)

Exclusion Criteria:

* 1\. History of primary hyperparathyroidism
* 2\. Use of combined hormonal contraceptive within the past 4 weeks
* 3\. Pregnancy or current pregnancy desire
* 4\. Prolactinoma associated with a known genetic syndrome
* 5\. Familial history of pituitary adenoma
* 6\. Renal failure (estimated glomerular filtration rate \<30 mL/min /1.73m2)
* 7\. IGF-1 level above the age-adjusted normal range of the local laboratory (IGF 1 \>1x ULNR)
* 8\. Idiopathic hyperprolactinemia (normal MRI) or presence of macroprolactinemia
* 9\. Concomitant mental condition rendering her unable to understand the nature, scope, and possible consequences of the study, and/or decompensated psychiatric disease (i.e. gambling or severe obsessive-compulsive disorder), as judged by the Investigator
* 10\. Chronic use of drugs related to hyperprolactinemia (such as metoclopramide, methyldopa, ranitidine, and opioid-related analgesics)
* 11\. Resistant prolactinoma, defined as non-normalization of PRL levels with 2mg/w of CAB
* 12\. Patients in the high dosage group who did not use 3.5mg/w of CAB for an entire 6 months (due to intolerance or non-compliance) or failed to achieve the target dose for any other reason
* 13\. Active malignant disease within the last 5 years, except basal and squamous cell carcinoma of the skin with complete local excision
* 14\. Any decompensated chronic condition (i.e. heart failure NYHA 3-4, diabetes with HbA1c \>8.5%, hypothyroidism with TSH \>10 mIU/L) that, in the opinion of the Investigator, would impede compliance, hinder completion of the study, compromise the well-being of the patient, or interfere with the study outcomes
* 15\. Male sex
* 16\. Cushing stigmas (moon face, muscle weakness, red striation) or suspicious
* 17\. Prior radiotherapy of the pituitary gland area for any reason
* 18\. Additional pituitary tumor-directed therapy, including temozolomide, everolimus, lapatinib, or cytotoxic chemotherapy
* 19\. Hepatopathy with AST/TGO or ALT/TGP \>3x the upper limit of normality

Where it's running

• Ufmg
  Belo Horizonte, Brazil Recruiting
• Unesp
  Botucatu, Brazil Recruiting
• Unb
  Brasília, Brazil Recruiting
• Unicamp
  Campinas, Brazil Recruiting
• Ufpr
  Curitiba, Brazil Recruiting
• Ufg
  Goiânia, Brazil Recruiting

Study contacts

• Study coordinator: Andrea Glezer, MD, PhD
• Email: andrea.glezer@hc.fm.usp.br
• Phone: 55 11 995791108

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cabergoline treatment targets and glucose metabolism in people with prolactinomas

  This trial will test whether different cabergoline treatment targets change blood sugar control in adults with prolactinomas.

  Recruiting Phase 4 University Hospital, Basel, Switzerland · Basel · NCT07045935

• Investigation of pituitary tumors and related disorders in children

  This study is trying to find out more about pituitary tumors in children by looking at their genes and how these tumors affect their health and emotions.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT00001595

• Red grape juice and metabolism in men with coronary disease

  Researchers will test whether daily red grape juice changes the blood metabolite profile in men with chronic coronary artery disease.

  Recruiting University of Sao Paulo General Hospital · São Paulo, São Paulo · NCT07777341

• TRIS: a mobile app with breathalyzer to support sobriety in alcohol use disorder

  A smartphone app with a connected breathalyzer tests for abstinence and uses small financial incentives to encourage sobriety for adults with AUD in Brazil.

  Recruiting University of Sao Paulo General Hospital · São Paulo, São Paulo · NCT07735585

• Escalation options for PAH patients already on dual therapy

  This trial tests whether adding a prostacyclin pathway drug or increasing sildenafil dose helps PAH patients at intermediate-to-high risk who aren’t at low risk despite dual therapy.

  Recruiting Phase 4 University of Sao Paulo General Hospital · São Paulo, São Paulo · NCT07713914

• SBRT-LATTICE-PATHY for Large Tumors

  This trial tests a targeted radiotherapy approach (SBRT-LATTICE-PATHY) to treat large, intractable solid tumors in adults.

  Recruiting Phase 2 University of Sao Paulo General Hospital · São Paulo, São Paulo · NCT07645261

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.